Toxic epidermal necrolysis and Stevens-Johnson syndrome;Syndromes de lyell et de Stevens-Johnson

Revue du Praticien

Volumn 57, Issue 11, 2007, Pages 1165-1170

  Roujeau, Jean Claude ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CARBAMAZEPINE; COTRIMOXAZOLE; LAMOTRIGINE; MELOXICAM; NEVIRAPINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; SALAZOSULFAPYRIDINE; SULFADIAZINE; SULFADOXINE; SULFAFURAZOLE; TENOXICAM;

BLISTER; CLINICAL FEATURE; EPIDERMOLYSIS; HUMAN; MORTALITY; PROGNOSIS; REVIEW; SKIN BIOPSY; SKIN EPITHELIUM; STEVENS JOHNSON SYNDROME; SURVIVAL; TOXIC EPIDERMAL NECROLYSIS;

ADULT; BIOPSY; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; FRANCE; GENETIC COUNSELING; HUMANS; PROGNOSIS; RISK FACTORS; SKIN; STEVENS-JOHNSON SYNDROME;

EID: 34347378481     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
3. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004;428:86.
4. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
5. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
6. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-15.
7. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-5.
8. Azukizawa H, Kosaka H, Sano S, et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur J Immunol 2003;33:1879-88.
9. Roujeau JC, Gelard X, Bensussan A. Nécrolyse épidermique, mécanismes de l'apoptose des kératinocytes. Med Sci (Paris) 2006;22:188-91.
10. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
11. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): clinical experience to date. Drugs 2005;65:2085-90.
12. Hung SL, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. PNAS 2005;102:4134-9.
13. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome... ethnicity matters. Pharmacogenomics J 2006;6:265-8.